Publikationen der ALS-Forschungsgruppe an der Charité
Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme
Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J,
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spastic using tetrahydrocannabinol:cannabidiol (THC:CBD)
Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B,
Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, Münch C,
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S,
Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Kettemann D, Funke A, Maier A, Rosseau S, Meyer R, Spittel S,
Interleukin-1 Antagonist Anakinra in Amyotriphic Lateral Sclerosis – A Pilot Study
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
Ludolph AC, Dorst J, Dreyhaupt J,
Prognostic factors in ALS: a comparison between Germany and China
Dorst J, Chen L, Rosenbohm A,
GABA B receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis
Schumacher H, Meyer T, Prüss H.
Comprehensive analysis of the mutation spectrum in 301 German ALS families
Müller K, Brenner D, Weydt P,
Therapeutic decision in ALS patients: cross-cultural differences and clinical implications
Andersen PM, Kuzma-Kozakiewicz M, Keller J,
The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy
Rosenbohm A, Hirsch S, Volk AE,
Hot-spot KIF5A mutations cause familial ALS
Brenner D, Yilmaz R, Müller K,
July 2017 ENCALS statement on edaravone
Al-Chalabi A, Andersen PM, Chandran S,
Genome-wide association analysis identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
van Rheenen W, Shatunov A, Dekker
